Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $133.00.

A number of brokerages have recently weighed in on ORKA. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Mizuho set a $120.00 target price on Oruka Therapeutics in a report on Thursday, September 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th.

Oruka Therapeutics Stock Performance

ORKA opened at $102.86 on Monday. The stock’s 50-day moving average price is $88.22 and its 200 day moving average price is $70.57. Oruka Therapeutics has a 12-month low of $25.23 and a 12-month high of $115.51. The firm has a market cap of $6.81 billion, a price-to-earnings ratio of -50.67 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president directly owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This represents a 39.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider owned 31,771 shares of the company’s stock, valued at $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 179,950 shares of company stock worth $16,492,680. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Oruka Therapeutics in the second quarter valued at about $474,916,000. Remedium Capital Partners LLC raised its holdings in Oruka Therapeutics by 0.9% in the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after acquiring an additional 13,247 shares in the last quarter. Jupiter Topco LLC acquired a new position in Oruka Therapeutics during the 2nd quarter worth $130,968,000. Avidity Partners Management LP increased its position in shares of Oruka Therapeutics by 15.1% in the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Candriam S.C.A. raised its stake in shares of Oruka Therapeutics by 2.6% in the 1st quarter. Candriam S.C.A. now owns 411,006 shares of the company’s stock valued at $20,160,000 after purchasing an additional 10,497 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.